Documentos relacionados

1. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
2. The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study.
3. Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures.
4. Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis.
5. In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
6. In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
7. 5-ASAs in Crohn's Disease: Time to Stop the Salicylate?
8. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
9. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
10. A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.